Compare NATR & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NATR | RXST |
|---|---|---|
| Founded | 1972 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.4M | 417.3M |
| IPO Year | N/A | 2021 |
| Metric | NATR | RXST |
|---|---|---|
| Price | $21.17 | $12.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 11 |
| Target Price | ★ $21.33 | $11.30 |
| AVG Volume (30 Days) | 182.3K | ★ 904.7K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $474,542,000.00 | $142,085,000.00 |
| Revenue This Year | $7.30 | N/A |
| Revenue Next Year | $3.44 | $4.18 |
| P/E Ratio | $26.24 | ★ N/A |
| Revenue Growth | 6.62 | ★ 10.75 |
| 52 Week Low | $11.01 | $6.32 |
| 52 Week High | $21.64 | $44.33 |
| Indicator | NATR | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 67.20 | 74.65 |
| Support Level | $20.35 | $11.20 |
| Resistance Level | $21.46 | $10.12 |
| Average True Range (ATR) | 0.92 | 0.69 |
| MACD | -0.06 | 0.22 |
| Stochastic Oscillator | 79.74 | 98.93 |
Natures Sunshine Products Inc is a natural health and wellness company, predominantly engaged in the manufacturing and selling of nutritional and personal care products. It offers products related to Weight management, General health, Cardiovascular, Digestive, Immune, and Personal care. The company operates in four segments namely, Asia which is also its key revenue generating market, Europe, North America, Latin America, and Other.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.